TELA Bio (NASDAQ:TELA) Posts Earnings Results

TELA Bio (NASDAQ:TELA) issued its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports. TELA Bio had a negative return on equity of 433.58% and a negative net margin of 48.37%.

Here are the key takeaways from TELA Bio’s conference call:

• Management said the U.S. commercial reset is showing early proof points, with the field force now fully staffed and new hires ramping toward expected productivity inflection points in the second half of 2026.
• TELA launched OviTex LTR in the U.S., a fully resorbable tissue-based hernia repair option, and said early surgeon feedback has been overwhelmingly positive. The company believes it broadens the portfolio and could help attract new surgeons.
• International momentum was strong, with Europe revenue up 41% year over year, led by the U.K. and supported by validation from the NHS supply chain value-based procurement evaluation.
• First-quarter revenue rose 3% to $19.1 million, while gross margin was 66% and operating loss was flat year over year at $10.5 million. The company reiterated full-year 2026 guidance for at least 8% revenue growth and Q2 revenue of about $20 million.
• OviTex PRS revenue was essentially flat year over year, and management said utilization dipped because several high-volume implanters were unavailable. The company is trying to reduce this concentration risk by training more surgeons per account.

TELA Bio Stock Up 5.1%

TELA Bio stock traded up $0.05 during midday trading on Tuesday, reaching $1.02. The company’s stock had a trading volume of 318,830 shares, compared to its average volume of 202,797. The stock has a market capitalization of $45.67 million, a P/E ratio of -1.23 and a beta of 1.30. The company has a debt-to-equity ratio of 8.82, a current ratio of 4.20 and a quick ratio of 3.59. The stock’s 50-day simple moving average is $0.75 and its 200-day simple moving average is $0.96. TELA Bio has a 52-week low of $0.50 and a 52-week high of $2.20.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TELA shares. Piper Sandler dropped their price objective on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating for the company in a research note on Wednesday, March 25th. Canaccord Genuity Group dropped their price target on shares of TELA Bio from $4.00 to $2.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Lake Street Capital dropped their price objective on TELA Bio from $3.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, March 25th. Citizens Jmp lowered their price objective on shares of TELA Bio from $5.00 to $3.00 and set a “market outperform” rating for the company in a research report on Friday, March 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TELA. Citadel Advisors LLC raised its holdings in shares of TELA Bio by 161.3% in the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after buying an additional 21,781 shares during the last quarter. Susquehanna International Group LLP raised its holdings in shares of TELA Bio by 551.2% in the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock worth $128,000 after buying an additional 72,594 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of TELA Bio by 101.4% in the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock worth $152,000 after buying an additional 64,800 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of TELA Bio in the fourth quarter worth $48,000. Hedge funds and other institutional investors own 94.35% of the company’s stock.

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.